FDA Grants Breakthrough Device Designation to Acrivon's ACR-368 OncoSignature Test for Endometrial Cancer
核心洞察
The FDA has awarded Breakthrough Device designation to Acrivon Therapeutics' ACR-368 OncoSignature assay, designed to identify endometrial cancer (搜索) patients most likely to respond to ACR-368 treatment.
In a Phase II trial, the ACR-368 OncoSignature assay demonstrated impressive results, with OncoSignature-positive endometrial cancer (搜索) patients showing a 62.5% confirmed overall response rate.
The multiplex immunofluorescence assay is expected to enhance treatment effectiveness for life-threatening conditions, marking a significant advancement in precision oncology.
Acrivon Therapeutics (NASDAQ: ACRV) has achieved a significant milestone as the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to its ACR-368 OncoSignature assay, a diagnostic tool designed for endometrial cancer (搜索) patient selection.
The multiplex immunofluorescence assay serves as a companion diagnostic tool for ACR-368, Acrivon's lead drug candidate. This innovative diagnostic approach aims to identify patients who are most likely to benefit from ACR-368 therapy, representing a step forward in precision medicine for gynecologic cancers.
Clinical Evidence Supporting Breakthrough Status
The FDA's decision was supported by compelling clinical data from an ongoing registrational-intent Phase IIb trial (搜索). The study demonstrated particularly promising results in endometrial cancer (搜索) patients, with ACR-368 OncoSignature-positive (BM+) patients achieving a confirmed overall response rate of 62.5%. This remarkable response rate underscores the potential of the biomarker-driven patient selection strategy.
Significance of Breakthrough Device Designation
The Breakthrough Device designation is reserved for medical devices that demonstrate potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions. This designation may expedite the development and regulatory review process, potentially accelerating patient access to this precision medicine approach.
Clinical Trial Progress
The ACR-368 OncoSignature assay is currently being evaluated in a registrational-intent Phase IIb trial (搜索), which includes patients with locally advanced or metastatic, recurrent endometrial cancer (搜索), along with other tumor types. The trial's design reflects the growing trend toward biomarker-guided patient selection in oncology clinical development.
This development represents a significant advance in the field of precision oncology, potentially offering a more targeted approach to treating endometrial cancer (搜索), a condition that often presents significant therapeutic challenges in its advanced stages.